{"name": "Apogenix",
 "permalink": "apogenix",
 "crunchbase_url": "http://www.crunchbase.com/company/apogenix",
 "homepage_url": "http://apogenix.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "contact@apogenix.com",
 "phone_number": "49-(0)-6221-58608-0",
 "description": "Clinical Stage Biopharmaceutical Company",
 "created_at": "Tue Feb 28 13:03:48 UTC 2012",
 "updated_at": "Tue Feb 28 13:15:30 UTC 2012",
 "overview": "\u003Cp\u003EApogenix is a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases. The compound\u00b4s mechanism of action is either based on the targeted modulation of the programmed cell death (a.k.a. apoptosis - \u1f01\u03c0\u03cc\u03c0\u03c4\u03c9\u03c3\u03b9\u03c3 is used in Greek to describe the \u0026#8220;falling off\u0026#8221; of leaves from trees) or on the inhibition of tumour cell growth. The lead product candidate of the company, APG101, is currently in a controlled phase II proof of concept study with GBM patients (GBM: Glioblastoma multiforme). \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       98],
      "assets/images/resized/0017/6150/176150v1-max-150x150.jpg"],
     [[250,
       164],
      "assets/images/resized/0017/6150/176150v1-max-250x250.jpg"],
     [[267,
       176],
      "assets/images/resized/0017/6150/176150v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$10M",
 "funding_rounds":
  [{"round_code": "c",
    "source_url": "http://onbiovc.com/apogenix-gmbh-series-c-10m/",
    "source_description": "Apogenix, GmbH: Series C $10M",
    "raised_amount": 10000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 2,
    "funded_day": 28,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "dievini Hopp Biotech Holding",
         "permalink": "dievini-hopp-biotech-holding",
         "image":
          {"available_sizes":
            [[[150,
               44],
              "assets/images/resized/0010/1829/101829v1-max-150x150.jpg"],
             [[250,
               73],
              "assets/images/resized/0010/1829/101829v1-max-250x250.jpg"],
             [[284,
               84],
              "assets/images/resized/0010/1829/101829v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Im Neuenheimer Feld 584",
    "address2": "",
    "zip_code": "69120",
    "city": "Heidelberg",
    "state_code": null,
    "country_code": "DEU",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        120],
       "assets/images/resized/0017/6151/176151v1-max-150x150.jpg"],
      [[250,
        200],
       "assets/images/resized/0017/6151/176151v1-max-250x250.jpg"],
      [[450,
        361],
       "assets/images/resized/0017/6151/176151v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}